Carisma Therapeutics (CARM) announced the expansion of in vivo chimeric antigen receptor macrophage and monocyte collaboration with Moderna, Inc. (MRNA) to include the nomination of two targets for the treatment of autoimmune diseases. Carisma and Moderna will leverage Carisma's CAR-M technology and Moderna's mRNA/LNP platform to develop in vivo macrophage engineering approaches in the nominated autoimmune disease targets. Carisma will receive research funding and is eligible to receive development, regulatory, and commercial milestone payments, plus royalties on net sales of any products that are commercialized under the collaboration. Carisma will be responsible for the discovery and optimization of development candidates. Moderna will lead the clinical development and commercialization of therapeutics.
Carisma retains all rights in autoimmune disease beyond the two nominated targets, which will be exclusively partnered with Moderna.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.